Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.

Nathan SD, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Morgenthien EA, Limb SL, Wells AU.

Chest. 2018 Nov 22. pii: S0012-3692(18)32769-7. doi: 10.1016/j.chest.2018.11.008. [Epub ahead of print]

2.

Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients.

Bessa V, Bonella F, Ohshimo S, Weinreich G, Kleibrink B, Costabel U, Aigner C, Kamler M, Taube C, Sommerwerck U.

Transpl Immunol. 2018 Nov 1. pii: S0966-3274(18)30082-0. doi: 10.1016/j.trim.2018.10.006. [Epub ahead of print]

PMID:
30391371
3.

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.

Wang Z, Bonella F, Li W, Boerner EB, Guo Q, Kong X, Zhang X, Costabel U, Kreuter M.

Respiration. 2018;96(6):571-587. doi: 10.1159/000492336. Epub 2018 Oct 11. Review.

PMID:
30308515
4.

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2018 Sep 14. pii: S2213-2600(18)30339-4. doi: 10.1016/S2213-2600(18)30339-4. [Epub ahead of print]

PMID:
30224318
5.

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.

Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G.

Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.

6.

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.

Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, Maurer O, Heinemann S, Costabel U, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells A, Vasakova M, Pesci A, Sofia M, Klepetko W, Seeger W, Drakopanagiotakis F, Crestani B.

Respir Res. 2018 Jul 28;19(1):141. doi: 10.1186/s12931-018-0845-5.

7.

An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Ohshimo S, Costabel U, Shime N.

Respir Investig. 2018 Mar;56(2):97-99. doi: 10.1016/j.resinv.2017.12.003. Epub 2017 Dec 27. No abstract available.

PMID:
29548662
8.

[DGP Interstitial Lung Disease Patient Questionnaire].

Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Wälscher J, Wirtz H, Kirsten D.

Pneumologie. 2018 Jun;72(6):446-457. doi: 10.1055/s-0044-100207. Epub 2018 Feb 21. German.

PMID:
29466814
9.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
10.

Phenotypes of organ involvement in sarcoidosis.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O'Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.

PMID:
29371378
11.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

12.

Serum YKL-40 in workers at an indium-tin oxide production facility - Reply.

Bonella F, Costabel U; all co-authors.

Respirology. 2018 Mar;23(3):342. doi: 10.1111/resp.13237. Epub 2017 Dec 15. No abstract available.

PMID:
29243860
13.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

14.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

15.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

16.

Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

Ohshimo S, Guzman J, Costabel U, Bonella F.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170012. doi: 10.1183/16000617.0012-2017. Print 2017 Sep 30. Review.

17.

Idiopathic pleuroparenchymal fibroelastosis (PPFE) - A case study of a rare entity.

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Bonella F.

Rev Port Pneumol (2006). 2017 Nov - Dec;23(6):352-355. doi: 10.1016/j.rppnen.2017.06.006. Epub 2017 Aug 3.

18.

[Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis].

Behr J, Günther A, Kreuter M, Koschel D, Prasse A, Pfeifer M, Costabel U.

Pneumologie. 2017 Sep;71(9):567-579. doi: 10.1055/s-0043-109856. Epub 2017 Aug 3. German.

PMID:
28772332
19.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):474. doi: 10.1055/s-0043-115504. Epub 2017 Jul 5. German. No abstract available.

PMID:
28679139
20.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Bonella F, Long X, He X, Ohshimo S, Griese M, Guzman J, Costabel U.

Respirology. 2017 Oct;22(7):1371-1378. doi: 10.1111/resp.13082. Epub 2017 May 31.

21.

[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017].

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2017 Jul;71(7):460-474. doi: 10.1055/s-0043-106160. Epub 2017 May 30. German. Erratum in: Pneumologie. 2017 Jul;71(7):474.

PMID:
28558396
22.

Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Costabel U, Stansen W, Stowasser S.

Am J Respir Crit Care Med. 2017 May 1;195(9):1275. doi: 10.1164/rccm.201610-2155LE. No abstract available.

PMID:
28459331
23.

Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.

Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.

Respiration. 2017;93(6):415-423. doi: 10.1159/000468546. Epub 2017 Apr 12.

24.

Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications.

Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantalocco P, Ryu JH, Chilosi M, Poletti V.

Respiration. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

25.

FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N.

Respir Med. 2017 Feb;123:105-109. doi: 10.1016/j.rmed.2016.12.007. Epub 2016 Dec 22.

PMID:
28137485
26.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
27.

Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.

Long X, He X, Ohshimo S, Griese M, Sarria R, Guzman J, Costabel U, Bonella F.

Eur Respir J. 2017 Feb 23;49(2). pii: 1501924. doi: 10.1183/13993003.01924-2015. Print 2017 Feb.

28.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Nov;48(5):1524-1526. doi: 10.1183/13993003.01482-2016. No abstract available.

29.

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.

Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M.

Thorax. 2017 Feb;72(2):148-153. doi: 10.1136/thoraxjnl-2016-208819. Epub 2016 Oct 5.

30.

[German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"].

Kreuter M, Birring SS, Wijsenbeek M, Wapenaar M, Oltmanns U, Costabel U, Bonella F.

Pneumologie. 2016 Nov;70(11):742-746. Epub 2016 Sep 21. German.

PMID:
27652583
31.

Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' reply.

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJF, Costabel U.

Lancet Respir Med. 2016 Sep;4(9):e48. doi: 10.1016/S2213-2600(16)30235-1. No abstract available.

PMID:
27599251
32.

Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Orphanet J Rare Dis. 2016 Aug 31;11(1):115. doi: 10.1186/s13023-016-0497-9.

33.

Sarcoidosis in America. Analysis Based on Health Care Use.

Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, Judson MA, Wolff G.

Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. doi: 10.1513/AnnalsATS.201511-760OC.

PMID:
27509154
34.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

35.

[Epidemiology and Clinical Presentation of Sarcoidosis].

Costabel U, Wessendorf TE, Bonella F.

Klin Monbl Augenheilkd. 2017 Jun;234(6):790-795. doi: 10.1055/s-0042-105569. Epub 2016 Jul 25. Review. German.

PMID:
27454307
36.

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Chest. 2016 Jul;150(1):251-3. doi: 10.1016/j.chest.2016.04.030. No abstract available.

37.

Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition.

Strek ME, Costabel U.

Curr Opin Pulm Med. 2016 Sep;22(5):442-9. doi: 10.1097/MCP.0000000000000298. Review.

PMID:
27379968
38.

MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.

Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U.

Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2.

39.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Jun;47(6):1776-84. doi: 10.1183/13993003.02087-2015. Epub 2016 Apr 21. Erratum in: Eur Respir J. 2016 Aug;48(2):593.

40.

How to handle IPF--the new Portuguese consensus document.

Costabel U, Bonella F.

Rev Port Pneumol (2006). 2016 Mar-Apr;22(2):70-2. doi: 10.1016/j.rppnen.2016.03.001. No abstract available.

41.

Pulmonary alveolar proteinosis: another autoimmune disease associated with sarcoidosis?

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Hetzel M, Drent M, Bonella F.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):90-4.

PMID:
27055841
42.

MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?

Mölleken C, Poschmann G, Bonella F, Costabel U, Sitek B, Stühler K, Meyer HE, Schmiegel WH, Marcussen N, Helmer M, Nielsen O, Hansen S, Schlosser A, Holmskov U, Sorensen GL.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):41-50.

PMID:
27055835
43.

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U.

Lancet Respir Med. 2016 May;4(5):381-9. doi: 10.1016/S2213-2600(16)00067-9. Epub 2016 Mar 31.

44.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

45.

[58-year old woman with primary biliary cirrhosis and crepitations].

Knoch CJ, Costabel U, Wessendorf T.

Dtsch Med Wochenschr. 2016 Feb;141(4):241. doi: 10.1055/s-0042-100629. Epub 2016 Feb 17. German. No abstract available.

PMID:
26886033
46.

Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.

Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, Lo KH, Barnathan ES; Sarcoidosis Investigators.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):289-95.

PMID:
26847095
47.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

48.

An Important Step Forward, but Still a Way to Go.

Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, Spagnolo P.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. No abstract available.

PMID:
26829426
49.

Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry.

Scheidl SJ, Kusej M, Flick H, Stacher E, Matzi V, Kovacs G, Popper HH, Costabel U, Olschewski H.

Respiration. 2016;91(1):26-33. doi: 10.1159/000442053. Epub 2015 Dec 12.

50.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

Supplemental Content

Loading ...
Support Center